Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Pluri Inc PLUR

Healthcare Biotechnology

Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical... see more

Add To Watchlist

Recent & Breaking News (NDAQ:PLUR)

Diamondback Energy Subsidiary Viper Energy Partners Reports Q4 Net Income $0.06/Unit vs $0.14/Unit in the Same Qtr. Last Year

Press Releases February 16, 2016

National Institutes of Health's NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem's PLX-R18 in the Treatment of Acute Radiation Syndrome

GlobeNewswire February 16, 2016

National Institutes of Health’s NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristem’s PLX-R18 in the Treatment of Acute Radiation Syndrome

Press Releases February 16, 2016

Pluristem Reports Second Quarter Fiscal 2016 Financial Highlights and Clinical Development Update

GlobeNewswire February 10, 2016

Pluristem to Present at Bio CEO & Investor Conference in New York City on February 8, 2016

GlobeNewswire January 26, 2016

Pluristem Receives U.S. FDA Clearance to Initiate Clinical Trial of PLX-R18 to Treat Insufficient Hematopoietic Recovery Following Bone Marrow Transplant

GlobeNewswire January 12, 2016

New Peer Reviewed Article Describes Mechanism of Action of PLX-PAD in Ameliorating Preeclampsia and Indicates Their Superiority Over Other Cells

GlobeNewswire January 6, 2016

U.S. Food & Drug Administration Grants Orphan Drug Designation to Pluristem's PLX-PAD Cells for Treatment of Severe Preeclampsia

GlobeNewswire December 31, 2015

Pluristem Reaches Agreement With Japan's PMDA on Protocol for Final Trial Targeting Market Entry Via Accelerated Pathway

GlobeNewswire December 21, 2015

Pluristem to Present at Phacilitate Cell & Gene Therapy World Conference in Washington DC on January 25-26, 2016

GlobeNewswire December 17, 2015

Pluristem and United Therapeutics End Licensing Agreement; Report Positive Data in Pulmonary Arterial Hypertension

GlobeNewswire December 8, 2015

Pluristem Signs MOU for Collaboration With Fukushima Medical University to Study PLX-R18 in Acute Radiation Syndrome

GlobeNewswire December 3, 2015

Pluristem to Present at Global Scientific & Investment Conferences in December

GlobeNewswire November 24, 2015

New Information Reveals Opportunity in Volatility - Research on Skullcandy, Gold Resource, McClatchy and Pluristem Therapeutics

Accesswire November 23, 2015

Cesca's Unique Approach to Regenerative Medicine - a Razor-Razor Blade Business Model

Accesswire November 19, 2015

Pluristem to Present New Data on PLX-R18 at American Society of Hematology's Annual Meeting

GlobeNewswire November 17, 2015

Pluristem Provides Corporate and Financial Highlights for First Quarter of Its Fiscal Year

GlobeNewswire November 9, 2015

Pluristem to Participate in Three European Life Sciences Conferences in November

GlobeNewswire October 27, 2015

Pluristem & Charite Expand Cooperation Agreement to Include Orthopedic Indications

GlobeNewswire October 12, 2015

Pluristem CEO Zami Aberman Elected to Board of Directors of the Alliance for Regenerative Medicine

GlobeNewswire October 7, 2015